Curatis Reports Significant Revenue Growth and Progress in Corticorelin Development

Curatis Holding AG reported a 57% increase in revenues for 2025, achieving CHF 10.8 million. The Swiss company reduced its net loss from CHF 4.3 million in 2024 to CHF 1.4 million in 2025. This financial improvement was driven by a 13% organic growth in its distribution business.

In 2025, significant progress was made in developing corticorelin for treating peritumoral brain edema. Following a successful FDA meeting, Curatis advanced towards a pivotal study. A license agreement with Neupharma Co., Ltd. in Japan was concluded, potentially bringing up to CHF 83.5 million in payments.

Looking to 2026, Curatis anticipates over 25% revenue growth and continued advancements in corticorelin's clinical preparations. A meeting with Japan's PMDA is scheduled for summer 2026, expected to drive further developments in the clinical study by 2027.